Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PI3Kα inhibition blocks osteochondroprogenitor specification and the hyper-inflammatory response to prevent heterotopic ossification

  • Valer, José Antonio
  • Deber, Alexandre
  • Wits, Marius
  • Pimenta-Lopes, Carolina
  • Goumans, Marie-José
  • Rosa, José Luis
  • Sánchez-Duffhues, Gonzalo
  • Ventura, Francesc
Reviewed Preprint: Published from the originalpreprint after peer reviewand assessment by eLife., Heterotopic ossification (HO) occurs following mechanical trauma and burns, or congenitally in patients suffering from fibrodysplasia ossificans progressiva (FOP). Recently, we demonstrated that inhibitors of phosphatidyl-inositol 3-kinase alpha (PI3Kα) may be a useful therapy for patients undergoing HO. In this study, using the already marketed BYL719/Alpelisib/Piqray drug, we have confirmed further these results, detailed the underlying mechanisms of action, and optimized the timing of the administration of BYL719. We found that BYL719 effectively prevents HO even when administered up to three to seven days after injury. We demonstrate in cell cultures and in a mouse model of HO that the major actions of BYL719 are on-target effects through the inhibition of PI3Kα, without directly affecting ACVR1 or FOP- inducing ACVR1R206H kinase activities. In vivo, we found that a lack of PI3Kα in progenitors at injury sites is sufficient to prevent HO. Moreover, time course assays in HO lesions demonstrate that BYL719 not only blocks osteochondroprogenitor specification, but also reduces the inflammatory response. BYL719 inhibits the migration, proliferation and expression of pro-inflammatory cytokines in monocytes and mast cells, suggesting that BYL719 hampers the hyper-inflammatory status of HO lesions. Altogether, these results highlight the potential of PI3Kα inhibition as a safe and effective therapeutic strategy for HO., We acknowledge the support fromPromega R&D. Alexandre Deber is a recipient of a F.P.I. fellowship from the Ministry of Scienceand Innovation (MCIN/AEI/ 10.13039/501100011033). Carolina Pimenta-Lopes is the recipient of aF.P.U. fellowship from the Spanish Ministry of Education. This research was supported by grantsPID2022-141212OA-I00, PDC2021-121776-I00 and PID2020-117278GB-I00 fromMCIN/AEI/10.13039/501100011033, co-funded by FEDER ‘Una manera de hacer Europa’ or‘NextGenerationEU’/PRTR; a grant 202038-30 from La Marató de TV3 and grants from IFOPA (ACTfor FOP) and FOPItalia. MW and MJG are sponsored by the Netherlands Cardiovascular ResearchInitiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, theNetherlands Organization for Health Research and Development, and the Royal NetherlandsAcademy of Sciences), PHAEDRA-IMPACT (DCVA) and DOLPHIN-GENESIS (CVON). GSD is alsosponsored by the Spanish Ministry of Science through the Ramón y Cajal grant RYC2021-030866-Iand the BHF-DZHK-DHF, 2022/23 award PROMETHEUS., Peer reviewed